DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Atenolol (Drug); Hydrochlorothiazide (HCTZ)) (Drug); Valsartan (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Novartis Pharma Ag, Principal Investigator, Affiliation: Novartis Pharmaceuticals


This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.

Clinical Details

Official title: A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites

Secondary outcome:

Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites

Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites

Mean Post-treatment Microcirculation at NaCl Injected Sites

Arterial Pressure Waveform Augmentation Index at the End of Treatment

Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment


Minimum age: 40 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Caucasian; male or female outpatients and age between 40-65 years of age, inclusive.

- At Visit 2 all patients must have a mean sitting diastolic blood pressure (msSBP) of

≥ 90 mmHg and < 110 mmHg. Exclusion Criteria:

- If a single reading for arterial hypertension in msSBP > 180 mmHg or msDBP > 110 mmHg

at any visit after randomization.

- Inability to discontinue all prior antihypertensive medications safely for a period

of 2 weeks prior to randomization.

- Known history of hypotensive symptoms or orthostatic hypotension.

- Concomitant use of statins or statin intake during the four weeks prior to Visit 1.

- Known Keith-Wagener grade III or IV hypertensive retinopathy.

- A history of heart failure (NYHA II-IV).

Locations and Contacts

Investigative Centers, Germany

Novartis Pharma Ag, Basel, Switzerland

Additional Information

Starting date: December 2005
Last updated: May 5, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017